Analyst Ratings for 4D Molecular Therapeutics
Portfolio Pulse from Benzinga Insights
4D Molecular Therapeutics (NASDAQ:FDMT) has received 5 bullish ratings and 1 indifferent rating from analysts in the last quarter. The average 12-month price target for the stock, according to 6 analysts, is $30.67, with a high of $36.00 and a low of $13.00. This average price target has increased by 46.05% over the past month.
July 05, 2023 | 2:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts have given 4D Molecular Therapeutics a bullish rating, with an average 12-month price target of $30.67, indicating potential upside.
The bullish ratings and increased price target suggest that analysts expect the stock to perform well in the future. This could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100